Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia.

摘要: Cardiovascular disease (CVD) is the leading cause of death worldwide and clinical manifestation atherosclerosis. Elevated LDL-cholesterol levels are first line therapy but increasing prevalence in type 2 diabetes mellitus (T2DM) has positioned cardiometabolic risk as most relevant parameter for treatment. Therefore, control this risk, characterized by dyslipidemia, hypertension, obesity, insulin resistance, become a major goal many experimental studies context CVD. In present review, we summarized trials recent anti-diabetic lipid-lowering therapies targeted to reduce Specifically, incretin-based therapies, sodium-glucose co-transporter inhibitors, proprotein convertase subtilisin kexin 9 inactivating described. Moreover, novel molecular mechanisms explaining CVD protection drugs reviewed here indicate effects on vascular cells, inflammatory cardiomyocytes, beyond their expected control. The revealed key mechanism prevention acute cardiovascular events restraining atherosclerosis at early stages, with decreased leukocyte adhesion, recruitment, foam cell formation, increased plaque stability diminished necrotic core advanced plaques. These emergent have promising future burden.